Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242201 | 0.87 | ESR1 (0.44) | ESR1ESR2TSHRACHELMNA | |
| SCHEMBL11023948 | 0.87 | ESR1 (0.44) | ESR1ESR2TSHRACHELMNA | |
| SCHEMBL14666537 | 0.84 | ESR1 (0.42) | ESR1ESR2TSHRACHELMNA | |
| SCHEMBL10150936 | 0.84 | ESR1 (0.42) | ESR1ESR2TSHRACHELMNA | |
| SCHEMBL9138483 | 0.82 | ESR1 (0.41) | ESR1ESR2TSHRACHELMNA | |
| SCHEMBL10613820 | 0.82 | ESR1 (0.41) | ESR1ESR2TSHRACHELMNA | |
| SCHEMBL63526 | 0.79 | ESR1 (0.70) | ESR1ESR2TSHRACHELMNA | |
| SCHEMBL239179 | 0.79 | ESR1 (0.48) | ESR1ESR2TSHRACHELMNA | |
| SCHEMBL439492 | 0.79 | ESR1 (0.48) | ESR1ESR2TSHRACHELMNA | |
| SCHEMBL92396 | 0.79 | ESR1 (0.48) | ESR1ESR2TSHRACHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10422036-B2 | Suppressing aging of platinum group metal particles in a catalytic converter | GM Global Technology Operations LLC (US) | 2019-09-24 | — | — | US | claimed |
| CN-106607103-B | Inhibit the aging of platinum group metal particles in catalytic converter | 通用汽车环球科技运作有限责任公司 | 2019-08-27 | — | — | CN | claimed |
| CN-106607103-A | SUPPRESSING AGING OF PLATINUM GROUP METAL PARTICLES IN CATALYTIC CONVERTER | 通用汽车环球科技运作有限责任公司 | 2017-05-03 | — | — | CN | claimed |
| US-20170114458-A1 | SUPPRESSING AGING OF PLATINUM GROUP METAL PARTICLES IN A CATALYTIC CONVERTER | GM Global Technology Operations LLC | 2017-04-27 | — | — | US | claimed |
| US-9216952-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2015-12-22 | — | — | US | claimed |
| EP-2411372-B1 | PROCESS FOR PREPARING AN ANTIVIRAL COMPOUND | ABBVIE BAHAMAS LTD (BS) | 2014-07-23 | — | — | EP | claimed |
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | claimed |
| EP-0067066-B2 | Dry-developing resist composition | FUJITSU LTD (JP) | 1994-01-12 | — | — | EP | claimed |
| EP-0067066-B1 | DRY-DEVELOPING RESIST COMPOSITION | FUJITSU LIMITED (JP) | 1985-12-18 | — | — | EP | claimed |
| EP-0067067-B1 | DRY-DEVELOPING NEGATIVE RESIST COMPOSITION | FUJITSU LIMITED (JP) | 1985-09-25 | — | — | EP | claimed |
| US-4481279-A | Dry-developing resist composition | FUJITSU LIMITED (JP) | 1984-11-06 | — | — | US | claimed |
| US-4464455-A | Dry-developing negative resist composition | FUJITSU LIMITED (JP) | 1984-08-07 | — | — | US | claimed |
| EP-0067067-A2 | Dry-developing negative resist composition | FUJITSU LIMITED (JP) | 1982-12-15 | — | — | EP | claimed |
| EP-0067066-A2 | Dry-developing resist composition | FUJITSU LIMITED (JP) | 1982-12-15 | — | — | EP | claimed |
| CN-111727271-B | Method for producing metal-containing films | 巴斯夫欧洲公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024053557-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND BATTERY | 株式会社日本触媒 | 2024-03-14 | — | — | WO | disclosed |
| US-20230253626-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-08-10 | — | — | US | disclosed |
| US-4464455-A | Dry-developing negative resist composition | FUJITSU LIMITED (JP) | 1984-08-07 | — | — | US | disclosed |
| EP-0067067-A2 | Dry-developing negative resist composition | FUJITSU LIMITED (JP) | 1982-12-15 | — | — | EP | disclosed |
| EP-0067066-A2 | Dry-developing resist composition | FUJITSU LIMITED (JP) | 1982-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ZC3HAV1, HAVCR2, MAVS | ESR1 4107/4885ESR2 4631/4885TSHR 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.